Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21798720 | 0.94 | KMT2A (0.76) | KMT2AMEN1TP53USP2POLB | |
| SCHEMBL3679372 | 0.94 | KMT2A (0.76) | KMT2AMEN1TP53USP2POLB | |
| SCHEMBL28609606 | 0.90 | MAOA (0.63) | HDAC6HDAC8HDAC2KMT2AMEN1 | |
| SCHEMBL8575405 | 0.87 | OGG1 (0.67) | HDAC6HDAC8HDAC2HDAC3HDAC1 | |
| SCHEMBL16592202 | 0.86 | KMT2A (0.74) | HDAC6HDAC8HDAC2KMT2AMEN1 | |
| SCHEMBL2461226 | 0.86 | MAPT (0.71) | KMT2AMEN1TP53USP2POLB | |
| SCHEMBL16583981 | 0.86 | KMT2A (0.74) | HDAC6HDAC8HDAC2KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL27743016 | 0.85 | OGG1 (0.64) | HDAC6HDAC8HDAC2HDAC3HDAC1 | |
| SCHEMBL24426120 | 0.85 | KMT2A (0.65) | KMT2AMEN1TP53USP2POLB | |
| SCHEMBL1753199 | 0.85 | RAB9A (0.81) | KMT2AMEN1TP53USP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115090-B2 | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-08-25 | — | — | US | claimed |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-09-27 | — | — | US | claimed |
| EP-1696898-B1 | ZN 2+ -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | UNIV OHIO STATE RES FOUND (US) | 2015-11-18 | — | — | EP | disclosed |
| US-9115090-B2 | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-08-25 | — | — | US | disclosed |
| US-8318808-B2 | Zn2+chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110281950-A1 | COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS | BAIOCCHI ROBERT A (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2011143314-A1 | COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS | ARNO THERAPEUTICS, INC (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011103563-A1 | METHODS AND COMPOSITIONS FOR INHIBITING AND PREVENTING THE GROWTH OF MALIGNANT MAST CELLS | ARNO THERAPEUTICS, INC (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20090137679-A1 | ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-05-28 | — | — | US | disclosed |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1696898-A2 | ZN 24 -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005055928-A2 | ZN2+ -CHELATING MOTIF-TETHERED SHORT -CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | HDAC1, BAZ2B, HDAC11 | HDAC6 13/4885HDAC8 14/4885HDAC2 5/4885 |
| US-20090137679-A1 | ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors | HDAC1, HDAC9, HDAC3 | HDAC6 13/4885HDAC8 9/4885HDAC2 4/4885 |
| US-20110281950-A1 | COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS | HDAC1, HDAC4, HDAC2 | HDAC6 10/4885HDAC8 9/4885HDAC2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.